Abstract #3097

Glioma staging with CEST asymmetry curves and amides/amines ratio.

Laura Mancini^1,2, Stefano Casagranda³, Francisco Torrealdea⁴, Marilena Rega⁴, Enrico De Vita^1,5, Bruno Lopez³, Sebastian Brandner^6,7, Benjamin Schmitt⁸, Patrick Liebig⁸, Eser Sanverdi¹, Xavier Golay^1,2, and Sotirios Bisdas^1,2

¹Lysholm Dept of Neuroradiology, National Hospital for Neurology & Neurosurgery, UCL Hospitals NHS Foundation Trust, London, United Kingdom, ²UCL Institute of Neurology, London, United Kingdom, ³Olea Medical, La Ciotat, France, ⁴University College of London Hospitals NHS Foundation Trust, London, United Kingdom, ⁵Biomedical Engineering Department, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom, ⁶Department of Neurodegenerative Disease, Institute of Neurology UCL, London, United Kingdom, ⁷National Hospital for Neurology & Neurosurgery, UCL Hospitals NHS Foundation Trust, London, United Kingdom, ⁸Siemens Healthcare Limited, Erlangen, Germany

Gliomas are the most common primary brain tumour, whose staging depends on the IDH and 1p/19q status and is reflected in different prognoses and clincal management. CEST is a highly sensitive MRI technique detecting amide- and amine-containing mobile proteins. The CEST amides/amines ratio has been proposed as a measure of pH in stroke. We show that CEST amides/amines ratio is much more sensitive than separate amides and amines CEST in differentiating gliomas with the best prognosis (IDH-mutant_1p/19q-retained) from those with the worst prognosis (IDH-wildtype). The different shapes in CEST asymmetry spectra could also potentially help in glioma staging.

This abstract and the presentation materials are available to members only; a login is required.

Join Here